TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07064122: A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of AZD2962, an IRAK4 Inhibitor, as Monotherapy and in Combination With Other Agents, in Participants With

Sponsor: AstraZeneca · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 72 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$376,992

Rescue Site Savings

+$251,328

Unlock Full NCT07064122 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07064122 Rescue Dossier →